Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand Targretin Symptom Trial Could Support Use For Early CTCL

Executive Summary

A trial focusing on symptom improvement of cutaneous T-cell lymphoma patients could demonstrate the utility of Ligand's Targretin for patients with early stage CTCL, FDA's Oncologic Drugs Advisory Committee said Dec. 13.

You may also be interested in...



Targretin Is Second Product In Ligand CTCL Therapy Triple Offering

The approval of Targretin capsules is the second step in Ligand's plan to offer patients with cutaneous T-cell lymphoma treatment options for all stages of the disease. The company currently markets Ontak and recently submitted an NDA for Targretin Gel.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel